Keyword
Quick search:
Content Search
Result Content Research
Result Content Research
1 Operational Highlights and Financial Results for the Year Ended June 30, 2021
2 Mesoblast's Novartis-partnered COVID-19 cell therapy hits a wall as FDA requests new trial
3 Mesoblast (ASX:MSB) shares rise as CEO reassures market on new FDA questions
4 2021 Pipeline Insight Report on Myocardial Infarction
5 Mesoblast shares dive 16pc as FDA raises more questions
6 Remestemcel-L Therapy for COVID-19–Associated Multisystem Inflammatory Syndrome in Children
7 Remestemcel-L reduces ARDS mortality in those under 65 years old
8 Remestemcel-L Reduces Mortality in Patients Less Than 65 Years Old With Moderate/Severe COVID-19
9 Covid-19 roundup: Pfizer, Merck start late-stage trials for Covid-19 pills; Merck begins PhIII study on post-exposure treatment
10 Mesoblast outlines results from trial of remestemcel-L in COVID-19
11 Mesoblast reports 90-day enhanced survival outcomes for remestemcel-L
12 Update on Remestemcel-L For the Treatment of COVID-19 ARDS and Steroid-Refractory Acute GVHDQuarterly Activity Report
13 Mesoblast Corporate Update and Financial Results Webcast
14 Remestemcel-L Fast Tracked for ARDS Due to COVID-19
15 FDA Issues Complete Response Letter to Remestemcel-L for Pediatric Steroid-Refractory Acute GVHD
16 Novartis Inks $1.35 Billion Deal with Mesoblast for Remestemcel-L for COVID-19 ARDS
17 Mesoblast Shares Plunge After Stem Cell Therapy Fails COVID-19 Study
18 The Short Report
19 Hot Stocks: LCID's PIPE nightmare; Oil-related stocks suffer; PVH hits high; MESO drops again; PLAN rallies
20 Top broker tips Mesoblast (ASX:MSB) share price to double in value
21 FDA: More Data on Remestemcel-L for Graft Versus Host Disease Needed
22 FDA Grants Fast Track Designation for Remestemcel-L in the
23 Mesoblast's stem cell therapy fails to meet primary endpoint in COVID-19 study
24 First-in-human trial to study remestemcel-L as Crohn's disease therapy launched
25 ASX 200 rises, Harvey Norman falls, Mesoblast sinks
26 Remestemcel-L Looks Promising in COVID-19 Patients With Moderate to Severe ARDS
27 Appendix 4C Quarterly Activity Report
28 Operational Highlights and Financial Results for the Period Ended March 31, 2021
29 Randomized Controlled Study Using Direct Injection of Remestemcel-L Into Inflamed Gut of Patients With Crohn's Disease and Ulcerative Colitis
30 Mesoblast Shares 90-Day Survival Outcomes After Remestemcel-L From COVID-19 ARDS Trial
31 Expanded access for remestemcel-L in COVID-19 infected children
32 Improved Outcomes in Inflammatory Lung Disease With
33 Can These Fallen Angels Regain Their Wings?
34 Salvaging six small caps
35 Mesoblast
36 ASX Health Stocks: Beamtree gets on the M&A trail while Creso Pharma eyes NASDAQ listing
37 Clinical Outcomes Using RYONCIL™ (remestemcel-L) in Children and Adults With Severe Inflammatory Graft Versus Host
38 Stem cell therapy trial for COVID-19 advised to continue
39 After Mesoblast COVID-19 drug flop, Novartis tries again with Molecular Partners
40 Mesoblast Presents Respiratory Function Results of COVID-19
41 Which ASX shares are leading the way on the ASX 300 today?
42 Mesoblast Provides Remestemcel-L Update and Quarterly Activity Report
43 The Pharma Letter Podcast — Episode 2 — Non-opioid analgesics
44 FDA grants Fast Track designation to COVID-19 ARDS treatment
45 Remestemcel-L Improves Respiratory and Functional Outcomes
46 CRP Levels Predict Response to Mesenchymal Stromal Cell Infusions in COPD
47 Mesoblast Wins 2020 Fierce Biotech Innovation of the Year Award for remestemcel-L
48 Promising Results for Stem Cell Treatment of Degenerative Disc Disease
49 US FDA Advisory Committee Votes Nine to One in Favor of
50 Mesoblast's Stem Cell Therapy Shows 83% Survival in Ventilator-Dependent COVID-19 Patients
51 Mesoblast's Revascor fails to meet primary endpoint in phase III chronic heart failure trial
52 Clinically Meaningful Outcomes Using Remestemcel-L In Patients With Chronic Graft Versus Host Disease
53 Mesoblast Operational Highlights and Upcoming Milestones
54 Mesoblast Operational and Financial Highlights for Quarter Ended December 31, 2020
55 MUSC Children's Hospital uses new method to treat rare MIS-C
56 Pandemic Highlights Opportunities, Challenges for Exosomes and Related Cell Therapies
57 Umbilical Cord Stem Cells Show Promise as COVID-19 Therapy
58 First Patients Dosed in Phase 2/3 Randomized Controlled Trial
59 Novartis signs $50 million deal for Mesoblast cell therapy for COVID, beyond
60 BRIEF-Mesoblast Says First Patients Dosed In Controlled Trial Of Remestemcel-L For Covid-19 Acute Respiratory Distress Syndrome
61 FDA OKs stem cell therapy for kids with inflammatory syndrome linked to COVID-19
62 Mesoblast Closes US$110/A$138 Million Financing Led by US Strategic Investor Group
63 Stem Cell Therapy Seen to Help COPD Patients with Severe Inflammation
64 Mesoblast preps first filings for GVHD drug after phase 3 win
65 Expanded Access Protocol Initiated for Compassionate Use of
66 Mesoblast To Evaluate Anti-Inflammatory Cell Therapy
67 BRIEF-Mesoblast Announces 83% Survival In COVID-19 Patients With ARDS Treated With Remestemcel-L
68 Clinical Catch-Up: July 19-23
69 Shock as FDA rejects Mesoblast's Ryoncil in paediatric graft versus host disease
70 Clinical Catch-Up: July 12-16
71 Texas Heart Institute to participate in global stem cell study to treat ARDS due to COVID
72 Clinical Catch-Up: February 15-19
73 Mesoblast spins a PhIII cell therapy miss in heart failure as a win, highlighting positive mortality data
74 COVID-19 cell therapy drives Mesoblast to seek manufacturing muscle
75 Mesoblast Limited: Is Stemcell Therapy Ready For Prime Time?
76 Mesoblast: The Future Looks Bleak
77 Mesoblast Needs A Solution To MSC Scalability Issues
78 What will 2021 do to Mesoblast’s (ASX:MSB) share price?
79 FDA grants priority review to Ryoncil for certain children with acute GVHD
80 Big turnout for first in series of free middle school vaccine events
81 Mesoblast’s friends maintain the faith
82 Mesoblast (MESO) Q1 2021 Earnings Call Transcript
83 Mesoblast Provides Topline Results From Phase 3 Trial of
84 Mesenchymal semifinals: ARDS hard but could Mesoblast's Ryoncil still thrill in GVHD?
85 Mesoblast receives $138m injection from US investors
86 Experimental stem cell therapy trial for COVID-19 initiated
87 Mesoblast Phase 3 Trial Shows That a Single Injection of
88 Cynata COVID-19 treatment trial expanded to other respiratory illnesses
89 Mesoblast talks Ryoncil, COVID-19 and manufacturing
90 Mesoblast (MESO) Q3 2021 Earnings Call Transcript
91 AdComm backs Mesoblast cell therapy despite manufacturing concerns
92 Mesoblast's Time May Be Up
93 Australia's Mesoblast plans to evaluate its stem cell therapy in patients infected with COVID-19
94 Clinical Catch-Up: October 12-16
95 Mesoblast Reports Substantial Operational Progress and Financial Results for the Year Ended June 30, 2020
96 Mesoblast Plunges as FDA Questions Cell-Therapy Manufacturing
97 Mesoblast (ASX:MSB) flags upcoming major private placement
98 Is Wall Street Wrong About Mesoblast?
99 Crohn's Disease Market Set to Observe Remunerative Growth at a CAGR of 7.6% During the Study Period 2018-30
100 FDA Action Alert: Aquestive, Eton and Mesoblast